Lower Prices for Weight-Loss Drugs Amid Ongoing Insurance Challenges
Originally Published 6 months ago — by TipRanks
Eli Lilly has reduced the price of its weight-loss drug Zepbound to around $500 per month, but access remains limited for many due to inconsistent insurance coverage, especially among Medicaid and Medicare recipients. Despite high demand and strong sales, insurance issues hinder broader affordability, though Eli Lilly's stock is rated a strong buy with a significant upside potential.